Beijing Biostar Pharmaceuticals Co., Ltd. (HKG:2563)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
3.650
-0.010 (-0.27%)
At close: Mar 10, 2026
-76.36%
Market Cap 1.33B
Revenue (ttm) 58.66M
Net Income (ttm) -139.45M
Shares Out 364.59M
EPS (ttm) -0.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 22,800
Average Volume 23,520
Open 3.660
Previous Close 3.660
Day's Range 3.650 - 3.660
52-Week Range 2.400 - 14.320
Beta n/a
RSI 48.70
Earnings Date May 28, 2026

About HKG:2563

Beijing Biostar Pharmaceuticals Co., Ltd., a synthetic biology-driven biopharmaceutical company, engages in the research, development, manufacture, and commercialization of oncology products in the People’s Republic of China. The company develops Utidelone injection, a microtubule inhibitor for the treatment of advanced and neoadjuvant breast cancer, advanced non-small cell lung cancer, gastric and esophageal cancer, brain metastasis, solid tumors, and glioblastoma. It is also involved in the development of Utidelone capsule that is in Phase II... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 131
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2563
Full Company Profile

Financial Performance

In 2024, HKG:2563's revenue was 71.87 million, an increase of 7.85% compared to the previous year's 66.64 million. Losses were -143.78 million, -24.19% less than in 2023.

Financial numbers in CNY Financial Statements

News

There is no news available yet.